[go: up one dir, main page]

WO2009057569A1 - Film-coated preparation - Google Patents

Film-coated preparation Download PDF

Info

Publication number
WO2009057569A1
WO2009057569A1 PCT/JP2008/069487 JP2008069487W WO2009057569A1 WO 2009057569 A1 WO2009057569 A1 WO 2009057569A1 JP 2008069487 W JP2008069487 W JP 2008069487W WO 2009057569 A1 WO2009057569 A1 WO 2009057569A1
Authority
WO
WIPO (PCT)
Prior art keywords
film
coated preparation
disclosed
coated
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/069487
Other languages
French (fr)
Japanese (ja)
Inventor
Takeshi Hamaura
Susumu Hasegawa
Ikumasa Ohno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to CN200880114044A priority Critical patent/CN101842096A/en
Priority to JP2009539054A priority patent/JPWO2009057569A1/en
Publication of WO2009057569A1 publication Critical patent/WO2009057569A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed is a film-coated preparation, in which the odor of a medicinal agent contained therein can be reduced. Specifically disclosed is a film-coated preparation which contains olmesartan medoxomil in its formulation, and which contains polyvinyl alcohol or a vinyl alcohol-containing copolymer in its film layer.
PCT/JP2008/069487 2007-10-29 2008-10-28 Film-coated preparation Ceased WO2009057569A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN200880114044A CN101842096A (en) 2007-10-29 2008-10-28 Film-coated preparation
JP2009539054A JPWO2009057569A1 (en) 2007-10-29 2008-10-28 Film coating formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007280843 2007-10-29
JP2007-280843 2007-10-29

Publications (1)

Publication Number Publication Date
WO2009057569A1 true WO2009057569A1 (en) 2009-05-07

Family

ID=40590960

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/069487 Ceased WO2009057569A1 (en) 2007-10-29 2008-10-28 Film-coated preparation

Country Status (5)

Country Link
JP (1) JPWO2009057569A1 (en)
KR (1) KR20100072317A (en)
CN (1) CN101842096A (en)
TW (1) TW200927197A (en)
WO (1) WO2009057569A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025035A1 (en) * 2009-08-31 2011-03-03 日新化成株式会社 Coating composition
JP2012193175A (en) * 2011-03-02 2012-10-11 Daiichi Sankyo Healthcare Co Ltd Rapidly soluble moisture-proof film-coated preparation and method for producing the same
EP2594277A4 (en) * 2010-07-07 2014-01-01 Japan Tobacco Inc TABLET CONTAINING FERRIQUE CITRATE
WO2014080365A1 (en) * 2012-11-23 2014-05-30 Ranbaxy Laboratories Limited Method of reducing an unpleasant odor of a pharmaceutical composition
WO2014188728A1 (en) * 2013-05-24 2014-11-27 持田製薬株式会社 Film-coating composition
EP2830618A4 (en) * 2012-03-30 2015-08-05 Dae Woong Pharma PHARMACEUTICAL COMPOSITION COMPRISING OLMESARTAN MEDOXOMIL AND ROSUVASTATIN OR SALT THEREOF
JP2016141630A (en) * 2015-01-30 2016-08-08 富士フイルム株式会社 Orally disintegrating tablets
JP2017001999A (en) * 2015-06-12 2017-01-05 富士フイルム株式会社 Method for producing drug-containing particles, drug-containing particles, pharmaceutical composition, and orally disintegrating tablet
WO2017164208A1 (en) * 2016-03-24 2017-09-28 第一三共株式会社 Medicine for treating renal disease

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102716100B (en) * 2012-07-12 2013-08-07 南京正大天晴制药有限公司 Tablets comprising olmesartan medoxomil and method for preparing same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002179741A (en) * 2000-10-04 2002-06-26 Basf Ag Water-soluble or water-dispersible (co)polymer of hydroxyalkyl (meth)acrylate, method of producing the same, and use of the same as coating agent, binder and/or film-forming excipient in pharmaceutical dosage form
WO2005019286A1 (en) * 2003-08-20 2005-03-03 Shionogi & Co., Ltd. Novel coating composition
WO2006123766A1 (en) * 2005-05-20 2006-11-23 Daichi Sankyo Company, Limited Film coated preparation containing dextrose
WO2006123765A1 (en) * 2005-05-20 2006-11-23 Daiichi Sankyo Company, Limited Film coated preparation
JP2007091620A (en) * 2005-09-28 2007-04-12 Kyoto Pharmaceutical Industries Ltd Film-coated tablet
JP2007197410A (en) * 2006-01-30 2007-08-09 Lion Corp Film coated tablets

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002179741A (en) * 2000-10-04 2002-06-26 Basf Ag Water-soluble or water-dispersible (co)polymer of hydroxyalkyl (meth)acrylate, method of producing the same, and use of the same as coating agent, binder and/or film-forming excipient in pharmaceutical dosage form
WO2005019286A1 (en) * 2003-08-20 2005-03-03 Shionogi & Co., Ltd. Novel coating composition
WO2006123766A1 (en) * 2005-05-20 2006-11-23 Daichi Sankyo Company, Limited Film coated preparation containing dextrose
WO2006123765A1 (en) * 2005-05-20 2006-11-23 Daiichi Sankyo Company, Limited Film coated preparation
JP2007091620A (en) * 2005-09-28 2007-04-12 Kyoto Pharmaceutical Industries Ltd Film-coated tablet
JP2007197410A (en) * 2006-01-30 2007-08-09 Lion Corp Film coated tablets

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025035A1 (en) * 2009-08-31 2011-03-03 日新化成株式会社 Coating composition
JP5730205B2 (en) * 2009-08-31 2015-06-03 日新化成株式会社 Coating composition
EP2594277A4 (en) * 2010-07-07 2014-01-01 Japan Tobacco Inc TABLET CONTAINING FERRIQUE CITRATE
JP2012193175A (en) * 2011-03-02 2012-10-11 Daiichi Sankyo Healthcare Co Ltd Rapidly soluble moisture-proof film-coated preparation and method for producing the same
EP2830618A4 (en) * 2012-03-30 2015-08-05 Dae Woong Pharma PHARMACEUTICAL COMPOSITION COMPRISING OLMESARTAN MEDOXOMIL AND ROSUVASTATIN OR SALT THEREOF
WO2014080365A1 (en) * 2012-11-23 2014-05-30 Ranbaxy Laboratories Limited Method of reducing an unpleasant odor of a pharmaceutical composition
WO2014188728A1 (en) * 2013-05-24 2014-11-27 持田製薬株式会社 Film-coating composition
JPWO2014188728A1 (en) * 2013-05-24 2017-02-23 持田製薬株式会社 Film coating composition
JP2016141630A (en) * 2015-01-30 2016-08-08 富士フイルム株式会社 Orally disintegrating tablets
JP2017001999A (en) * 2015-06-12 2017-01-05 富士フイルム株式会社 Method for producing drug-containing particles, drug-containing particles, pharmaceutical composition, and orally disintegrating tablet
WO2017164208A1 (en) * 2016-03-24 2017-09-28 第一三共株式会社 Medicine for treating renal disease

Also Published As

Publication number Publication date
JPWO2009057569A1 (en) 2011-03-10
TW200927197A (en) 2009-07-01
KR20100072317A (en) 2010-06-30
CN101842096A (en) 2010-09-22

Similar Documents

Publication Publication Date Title
WO2009057569A1 (en) Film-coated preparation
WO2010022154A3 (en) Release materials
MX2009010690A (en) Method and composition for zonal isolation of a well.
WO2011084593A3 (en) Abuse-resistant formulations
CR20110072A (en) DRUG ADMINISTRATION SYSTEM CONTAINING PROGESTINE
WO2011031558A3 (en) Toughened polyhydroxyalkanoate compositions
WO2010026433A3 (en) Polymeric material
WO2009023662A3 (en) Water-resistant, rub-resistant, sprayable, homogeneous sunscreen composition
WO2009129301A3 (en) Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
WO2007095600A3 (en) Disintegrable oral films
GEP20125410B (en) Solid preparation comprising alogliptin and pioglitazone
WO2009145581A3 (en) Oxide semiconductor and thin film transistor including same
CL2009000328A1 (en) Unit dosage form comprising a water soluble thin film matrix comprising a polyvinyl alcohol-polyethylene glycol graft copolymer as a water soluble matrix polymer and a steroid estrogen as active ingredient, wherein the film matrix has a thickness less than 300 um.
EP2399168A4 (en) Chemical amplification resist composition, and mold preparation method and resist film using the same
WO2009006218A3 (en) Personal care dissolvable films
WO2009014855A3 (en) Ink formulations and methods of making ink formulations
AU2007338403A1 (en) shRNA-mediated inhibition of expression of alpha-1. 6-fucosyltransferase
EP2338929B8 (en) Silicone-polymer-containing vinyl polymer powder and manufacturing method thereof, resin composition, and compact
WO2009016952A1 (en) Mold release film
WO2009076272A3 (en) Drug coated stent with endosome-disrupting conjugate
MX340436B (en) Stable pharmaceutical formulation with limited discoloration.
WO2008078727A1 (en) Pharmaceutical composition having improved dissolution property
MX2009005446A (en) Vaginal delivery system for mirtazapine.
UA102680C2 (en) Unit dosage form comprising a polyvinyl alcohol-polyethylene glycol graft copolymer and steroidal estrogen
WO2011124570A3 (en) Oral film formulation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880114044.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08845153

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009539054

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20107009312

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08845153

Country of ref document: EP

Kind code of ref document: A1